BeyondSpring Files 2023 Annual Report on Form 20-F
BYSI Stock | USD 1.64 0.07 4.09% |
Under 54% of BeyondSpring's investor base is interested to short. The analysis of the overall investor sentiment regarding BeyondSpring suggests that many traders are impartial. BeyondSpring's investing sentiment shows overall attitude of investors towards BeyondSpring.
BeyondSpring |
FLORHAM PARK, N.J., April 29, 2024 -- BeyondSpring Inc. , a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 29, 2024. The annual report on Form 20-F, which contains the Companys audited consolidated financial
Read at finance.yahoo.com
BeyondSpring Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeyondSpring can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeyondSpring Fundamental Analysis
We analyze BeyondSpring's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeyondSpring using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeyondSpring based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
BeyondSpring is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
BeyondSpring Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeyondSpring stock to make a market-neutral strategy. Peer analysis of BeyondSpring could also be used in its relative valuation, which is a method of valuing BeyondSpring by comparing valuation metrics with similar companies.
Peers
BeyondSpring Related Equities
ARMP | Armata Pharmaceuticals | 4.29 | ||||
ADTX | Aditxt | 2.94 | ||||
MCRB | Seres Therapeutics | 2.33 | ||||
SRZN | Surrozen | 1.44 | ||||
SLS | Sellas Life | 1.16 | ||||
FBRX | Forte Biosciences | 0.52 | ||||
KTTA | Pasithea Therapeutics | 0.75 | ||||
INKT | Mink Therapeutics | 1.59 | ||||
PLX | Protalix Biotherapeutics | 1.64 | ||||
ALVR | Allovir | 2.17 | ||||
MIST | Milestone Pharmaceuticals | 3.23 | ||||
ONCY | Oncolytics Biotech | 3.57 | ||||
SCPH | Scpharmaceuticals | 3.63 | ||||
RVPH | Reviva Pharmaceuticals | 5.78 | ||||
EYPT | Eyepoint Pharmaceuticals | 6.05 | ||||
CADL | Candel Therapeutics | 31.12 |
Complementary Tools for BeyondSpring Stock analysis
When running BeyondSpring's price analysis, check to measure BeyondSpring's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeyondSpring is operating at the current time. Most of BeyondSpring's value examination focuses on studying past and present price action to predict the probability of BeyondSpring's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeyondSpring's price. Additionally, you may evaluate how the addition of BeyondSpring to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |